BIO CEO & Investor Conference
Thanks for attending the 2023 BIO CEO & Investor Conference
Now in its 25th year, the BIO CEO & Investor Conference fuels the biotech industry as a premier event for C-Suite leaders and the investor and banking communities, focused on established and emerging publicly traded and select private biotech companies.
This year, it’s easier than ever to be a part of CEO. There will be two days of in-person meetings in New York, Feb 6-7, followed by two days of virtual partnering; giving you access to the best opportunities to grow your business from wherever you are.
Across four days, participate in one of the largest investor conferences where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through partnering, company presentations, and educational sessions on therapeutic advancements, market outlook, and policy priorities.
Kathy Fernando is a Senior Vice President and Global Head of the Partner of Choice Organization within the Business Innovation Office at Pfizer.
Lars Enstrom is a Managing Director on the Credit and Royalty team, focused on structured finance and royalty investments.
Praveen Tipirneni, MD, MBA is Chief Executive Officer of Morphic Therapeutic Inc. Previously, he was Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals...
BIO offers best-in-class programming for C-Suite leaders and the investor and banking communities, focused on established and emerging publicly traded and select private biotech companies.
BIO's CEO and Investor Conference Advisory Committee brings together some of the best and most influential leaders across the biotech industry.
Make the right connections with a robust list of potential investors, business development executives, and service providers.
Subscribe to BIO CEO & Investor Conference and receive timely event updates, exclusive content, partnering and programming announcements, and more.